These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11104613)

  • 1. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma.
    Sakuragi N; Nakajima A; Nomura E; Noro N; Yamada H; Yamamoto R; Fujimoto S
    Gynecol Oncol; 2000 Dec; 79(3):420-3. PubMed ID: 11104613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bowel injury caused by a catheter for Intraperitoneal chemotherapy--a case report].
    Yamauchi I; Higashi M; Yoshioka M; Koyama N; Hashimoto M; Takahashi K; Nakamura Y
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1713-6. PubMed ID: 8886051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
    Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
    Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
    Walker JL; Armstrong DK; Huang HQ; Fowler J; Webster K; Burger RA; Clarke-Pearson D
    Gynecol Oncol; 2006 Jan; 100(1):27-32. PubMed ID: 16368440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications associated with intraperitoneal chemotherapy catheters.
    Makhija S; Leitao M; Sabbatini P; Bellin N; Almadrones L; Leon L; Spriggs DR; Barakat R
    Gynecol Oncol; 2001 Apr; 81(1):77-81. PubMed ID: 11277654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
    Kehoe SM; Williams NL; Yakubu R; Levine DA; Chi DS; Sabbatini PJ; Aghajanian CA; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2009 May; 113(2):228-32. PubMed ID: 19254808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
    Malmström H; Carstensen J; Simonsen E
    Gynecol Oncol; 1994 Jul; 54(1):27-34. PubMed ID: 8020835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer.
    Kim SW; Paek J; Nam EJ; Kim SH; Kim JH; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2010 Oct; 152(2):195-9. PubMed ID: 20576343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intraperitoneal chemotherapy using CBDCA for malignant gynecological tumors].
    Shimizu A; Kimura T; Funatsu M; Hada Y; Tamura K; Taguchi A; Miyakawa Z; Notake Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1738-41. PubMed ID: 1530345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Problems associated with the administration of intraperitoneal therapy using the Port-A-Cath system.
    Almadrones L; Yerys C
    Oncol Nurs Forum; 1990; 17(1):75-80. PubMed ID: 2300507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intraperitoneal chemotherapy through implantable injection port in patients with advanced ovarian (or tubal) carcinoma].
    Ryuko K; Iwanari O; Moriyama M; Moriyama M; Nakayama S; Miyako J; Kitao M
    Gan To Kagaku Ryoho; 1991 Aug; 18(11):2052-7. PubMed ID: 1877848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
    Lentz SS; Miller BE; Kucera GL; Levine EA
    Gynecol Oncol; 2007 Jul; 106(1):207-10. PubMed ID: 17498782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laparoscopic placement of PAP catheters for intraperitoneal chemotherapy in ovarian carcinoma.
    Arts HJ; Willemse PH; Tinga DJ; de Vries EG; van der Zee AG
    Gynecol Oncol; 1998 Apr; 69(1):32-5. PubMed ID: 9570995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
    Black D; Levine DA; Nicoll L; Chou JF; Iasonos A; Brown CL; Sonoda Y; Chi DS; Leitao MM; Abu-Rustum NR; Ferguson SE; Barakat RR
    Gynecol Oncol; 2008 Apr; 109(1):39-42. PubMed ID: 18234300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of complications associated with catheter intraperitoneal chemotherapy of ovarian carcinoma].
    Wei LH; Qian HN; Li WF
    Zhonghua Fu Chan Ke Za Zhi; 1994 Dec; 29(12):732-4, 762-3. PubMed ID: 7712902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Functioning of implantable catheters of intraperitoneal chemotherapy].
    de Gramont A; Marpeau L; Demuynck B; Gonzalez-Canali G; Pigné A; Herbulot P; Lagadec B; Cady J; Couturier JY; Delfau S
    J Gynecol Obstet Biol Reprod (Paris); 1991; 20(3):381-5. PubMed ID: 1869783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
    Ivy JJ; Geller M; Pierson SM; Jonson AL; Argenta PA
    Gynecol Oncol; 2009 Sep; 114(3):420-3. PubMed ID: 19560189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complications in the intraperitoneal chemotherapy with the implantable intraperitoneal port and the strategy for the prevention of the complication].
    Maruyama M; Takamatsu H; Sugano N; Katada M; Ebuchi M
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1469-72. PubMed ID: 7574734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
    Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.